MBF Therapeutics Revenue and Competitors

USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • MBF Therapeutics's estimated annual revenue is currently $1.9M per year.(i)
  • MBF Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • MBF Therapeutics has 12 Employees.(i)
  • MBF Therapeutics grew their employee count by -40% last year.

MBF Therapeutics's People

NameTitleEmail/Phone
1
CEO & PresidentReveal Email/Phone
2
Chief Medical OfficerReveal Email/Phone
3
CSOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$9.1M59-9%N/AN/A
#10
$16.6M1073%N/AN/A
Add Company

What Is MBF Therapeutics?

MBF Therapeutics is a life science company developing and commercializing proprietary checkpoint inhibitor immunotherapy technology for cancer and infectious diseases in both animal and human health. T-cell activation precisely targets selected antigens associated with cancer cells or infectious pathogens while preventing T-cell exhaustion, thus, yielding a durable cell-mediated immunity. MBF Therapeutics has in-licensed checkpoint inhibitor technology from several sources. In addition, MBF Therapeutics has discovered novel proprietary immunomodulating technology. These combined with a proprietary nonviral delivery system (CaptaVaxâ„¢), in-licensed from the Southwest Research Institute, provides MBF Therapeutics with a powerful platform technology from which multiple innovative products can be developed for veterinary medicine and human health where cellular antigens are well defined.

keywords:N/A

N/A

Total Funding

12

Number of Employees

$1.9M

Revenue (est)

-40%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.9M120%N/A
#2
$1.5M12-40%N/A
#3
$1M12N/AN/A
#4
$1M12N/AN/A
#5
$1M12N/AN/A